This article has been updated

Abstract

Predicting the best treatment strategy from genomic information is a core goal of precision medicine. Here we focus on predicting drug response based on a cohort of genomic, epigenomic and proteomic profiling data sets measured in human breast cancer cell lines. Through a collaborative effort between the National Cancer Institute (NCI) and the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project, we analyzed a total of 44 drug sensitivity prediction algorithms. The top-performing approaches modeled nonlinear relationships and incorporated biological pathway information. We found that gene expression microarrays consistently provided the best predictive power of the individual profiling data sets; however, performance was increased by including multiple, independent data sets. We discuss the innovations underlying the top-performing methodology, Bayesian multitask MKL, and we provide detailed descriptions of all methods. This study establishes benchmarks for drug sensitivity prediction and identifies approaches that can be leveraged for the development of new methods.

Main

The success of precision medicine hinges on our ability to effectively translate genomic data into actionable, customized prognosis and treatment regimens for individual patients. This requires identifying a genomic disease signature from a patient, then matching it with the most effective therapeutic intervention. As a scientific community, we are moving toward this goal, but many questions still remain, including, what data are needed to develop these genomic signatures and what methods are needed to extract the appropriate information from high-dimensional genomic data sets? The first step in addressing these challenges is to generate comprehensive drug sensitivity profiling measurements across many drugs, many disease (sub)types, and many genomic profiling technologies. Several of these data sets have been generated with a focus on cancer biology1,2,3,4,5,6,7,8,9, and in particular breast cancer4,5,10,11,12,13,14. From these data, the bottleneck then becomes identifying robust computational approaches that connect genomic profiles to drug and disease response.

In the past 20 years, there has been measurable improvement in breast cancer outcomes with a steady decrease in mortality15. The identification of HER2 amplification and subsequent discovery of HER2-targeted therapies (e.g., trastuzumab (Herceptin), lapatinib (Tykerb)) demonstrates that the identification of genomic biomarkers can be used to effectively guide treatment decisions and improve outcomes. However, identification of such biomarkers is complicated by substantial genomic and epigenomic heterogeneity in breast cancer2,10,16,17, indicating that multiple 'drivers' may serve as targets for breast cancer treatment. Effective personalized treatments will require matching therapeutic interventions to the complex genomic context of each patient.

The ideal data set(s) to build predictive models linking genomic context to treatment would be systematically characterized drug sensitivities across a large cohort of patients, but these data are time-intensive to generate, prohibitively expensive, and limited in the scope of drugs that can be tested. Performing such assays in cell culture and focusing on breast cancer affords the opportunity to learn the factors that contribute to building effective predictive models in a tractable biological system; these factors can then be used for the design of marker-based clinical trials. Comparisons have shown that cell lines mirror many aspects of the 'omic' diversity found in primary tumors4,18,19, suggesting that they can be used as a proxy for characterizing the response to therapeutic interventions. Previous work has characterized relationships between genomic profiles and drug response1,3,6,7,20 and several drug sensitivity prediction algorithms have been proposed1,3,20,21,22,23; however, a thorough and unbiased comparison of such methods has not been reported.

The Dialogue for Reverse Engineering Assessment and Methods (DREAM) project (http://www.the-dream-project.org/) is the ideal framework to assess predictive models from researchers across the world. The DREAM project is organized around a community of data scientists, where high-impact data along with challenges are presented annually, participants submit their best models, and unbiased assessment is performed using standardized metrics and blinded gold standards. This effort results in a rigorous assessment and performance ranking of methods, and cultivates a community of scientists interested in biomedical research problems.

In collaboration with the NCI, we developed the NCI-DREAM drug sensitivity prediction challenge with the goal of identifying and benchmarking top-performing methods for predicting therapeutic response from genomic, proteomic, and epigenomic profiling data (hereafter referred to as profiling data sets) in breast cancer cell lines. The scientific community submitted 44 sets of predictions, providing a rich sampling of state-of-the-art algorithms. The submissions were rigorously scored against an unpublished and hidden gold-standard data set. We identify the top-performing methods and discuss the details of the top two performers. We relate trends in methodologies to overall performance, in particular, modeling nonlinearities in the data and the benefit of using prior knowledge, often in the form of biological pathways. Finally, we provide an analysis of the tested therapeutic compounds and cell line profiling data sets.

Results

Summary of data sets and challenge

We assembled a panel of 53 breast cancer cell lines, which have been previously profiled for DNA copy-number variation, transcript expression, mutations, DNA methylation and protein abundance20. In addition, dose-response values of growth inhibition were compiled for each cell line exposed to 28 therapeutic compounds (Fig. 1). (See Online Methods for a detailed description of the profiling data sets.)

Figure 1: The NCI-DREAM drug sensitivity challenge.
Figure 1

(a) Six genomic, epigenomic, and proteomic profiling data sets were generated for 53 breast cancer cell lines, which were previously described23. Drug responses as measured by growth inhibition were assessed after treating the 53 cell lines with 28 drugs. Participants were supplied with all six profiling data sets and dose-response data for 35 cell lines and all 28 compounds (training set). Cell line names were released, but drug names were anonymized. The challenge was to predict the response (ranking from most sensitive to most resistant) for the 18 held-out cell lines (test set). The training and test cell lines were balanced for cancer subtype, dynamic range and missing values (Supplementary Fig. 11). Submissions were scored on their weighted average performance on ranking the 18 cell lines for 28 compounds. (b) Dose-response values for the training and test cell lines displayed as heatmaps.

Outlined in Figure 1, participants were supplied with the full set of profiling data for all 53 cell lines, and drug response data for 35 cell lines for the 28 compounds. The gold-standard evaluation data set, which was hidden from the participants, consisted of drug-response data for the remaining 18 cell lines. Cell lines were assigned to the training and test data sets to ensure a balance of breast cancer subtypes.

Participants were challenged to predict a ranked list of the most sensitive (to be ranked first) to most resistant (to be ranked last) cell lines for each individual drug across all the 18 test cell lines. Assessment of predictions was based on participant's ranking of all 28 therapeutic compounds across all 18 test cell lines.

Characterizing methods to predict drug sensitivity

Participants submitted 44 sets of predictions that cover a range of methodologies. We assigned submissions to one of six categories: (i) kernel methods, (ii) nonlinear regression (regression trees), (iii) sparse linear regression, (iv) PLS (partial least-squares) or PC (principal component) regression, (v) ensemble/model selection and (vi) other (those methods not falling cleanly into the previous five categories). All methods are listed in Table 1 with a short description that covers pre- and postprocessing, along with the underlying methodology (expanded team summarizations can be found in Supplementary Table 1).

Table 1: NCI-DREAM drug sensitivity prediction methods

Preprocessing and feature selection are core components of building a predictor. In this challenge, features in the profiling data sets (P) far outnumber the total samples (N), increasing the risk of overfitting. To address this, teams often reduced the number of features modeled by correlating the features in the profiling data set to the dose-response data. Other preprocessing steps included principal component analysis, regularized regression (e.g., lasso, ridge or elastic nets) and mapping gene-level measurements to biological pathways.

Postprocessing includes summarizing or integrating predictions from individual algorithms or data sets into a final set of predictions. For instance, many participants built models for each of the six profiling data sets individually, and then integrated these models to derive the final cell line response predictions for submission. Most frequently, teams computed a weighted average across individual profiling data set predictions. Detailed descriptions of team methods can be found in Supplementary Note 1.

Evaluating drug sensitivity predictions

Team predictions were scored using a modified version of the concordance index (c-index)24, the probabilistic c-index (pc-index), where variation in the experimentally determined dose-response measurements was directly incorporated into the calculation. We present all dose-response values as −log10(GI50), where GI50 is the concentration that inhibited cell growth by 50% after 72 hours of treatment. Raw dose-response measurements can be found in Supplementary Table 2. A team's final score was calculated as the weighted average of the pc-index for all 28 tested compounds, which we termed the weighted, probabilistic c-index (wpc-index, see Online Methods and Supplementary Note 3). Drug weights reflect the statistical significance of the gold-standard cell-line ranking compared to a distribution of randomly generated predictions. We note that the range of the wpc-index will change according to experimental variation in the dose-response measurements, thus we also report a scaled version of the wpc-index to map the values to the range [0,1]. To verify scoring consistency, we also evaluated teams using a resampled Spearman correlation approach (Online Methods). Results from both scoring methods were consistent (ρ = 0.89; Supplementary Fig. 1); we present the wpc-index results in Table 1 and the resampled Spearman correlation results in Supplementary Table 3. Additionally, we explored a team's accuracy in predicting sensitive and resistant cell lines irrespective of predicted rank order (Supplementary Table 4 and Supplementary Fig. 2) and found a tight relationship between this measure of accuracy and the wpc-index (ρ = 0.78; Supplementary Fig. 3). For the top-performing method, wpc-index = 0.583, which corresponds to a balanced accuracy = 0.78. Details of this analysis can be found in Supplementary Note 2 with a mapping of the wpc-index to the sensitive and resistant balanced accuracy in Supplementary Table 5.

To evaluate the significance of an individual team score, we compared the wpc-index to a null model of randomly predicted dose-response values. For 34 of the 44 teams, the null model of randomly generated predictions could be rejected (two-sided, t-test, false-discovery rate (FDR) < 0.05) (Fig. 2a). These results indicate that many diverse methods can be implemented to make drug sensitivity predictions from pretreatment profiling data sets. Consistent with previous DREAM challenge results25, we observed that no single method category consistently outperformed the others (Fig. 2a and Table 1). This suggests that the separation in performance is heavily based on factors such as feature selection and method-specific implementations. Examples of innovative approaches from the two top-performing teams are presented in the following section.

Figure 2: Evaluation of individual drug sensitivity prediction algorithms.
Figure 2

Prediction algorithms (n = 44) are indexed according to Table 1. (a) Team performance was evaluated using the weighted, probabilistic concordance index (wpc-index), which accounts for the experimental variation measured across cell lines and between compounds. Overall team ranks are listed on top of each bar. The gray line represents the mean random prediction score. (b,c) Robustness analysis was performed by randomly masking 10% of the test data set for 10,000 iterations. Performing this procedure repeatedly generates a distribution of wpc-index scores for each team (b). Additionally, after each iteration, teams were re-ranked to create a distribution of rank orders (c). The top two teams were reliably ranked the best and second-best performers (one-sided, Wilcoxon signed-rank test for b and c, FDR 10−10).

All submissions were subjected to a robustness (resampling) analysis by randomly masking 10% of the gold-standard data set, then recalculating team scores (Fig. 2b,c). From this analysis, the top two teams were reliably ranked the best and second best, both when comparing team scores (one-sided, Wilcoxon signed-rank test, FDR < 10−10; Fig. 2b) and team ranks (one-sided, Wilcoxon signed-rank test, FDR < 10−10; Fig. 2c). When directly compared, the top-ranked team outperformed the second-best team for 91%, and the remaining teams, for over 99% of the resampled iterations. The second-best team outperformed the remaining teams for over 95% of the resampled iterations (Supplementary Fig. 4 and Supplementary Table 6); however, the third through fourteenth ranked teams were not statistically different (Supplementary Tables 6 and 7).

Of the 44 submissions, 23 used all six profiling data sets to make their predictions, 8 used five data sets, 4 used three data sets, 5 used two data sets and 4 used one data set. We compared the average rank performance of teams that used all six profiling data sets to teams using five or fewer data sets, but did not find a significant difference in their performance (average rank 22.7 versus 22.3). We explored several additional variables (missing values being imputed, outside information being used, method category) and found that only the inclusion of outside information in the form of annotated biological pathways26,27 or published drug response data sets1,3,4 improved the average team rank (17.4 versus 24.9; one-sided, Wilcoxon rank-sum test, p = 0.03).

The observation that integrating predictions across multiple, independent teams produces the most robust score has been previously made25. For such a 'wisdom of crowds' phenomenon to hold, individual predictions must provide complementary information derived from independent methods. We tested this phenomenon and found that the wisdom of crowds resulted in better performance (Supplementary Fig. 5a), along with increasingly robust predictions (i.e., greater mean, lower variance), by integrating greater numbers of teams (Supplementary Fig. 5b). Furthermore, predictions from the aggregation of a random subset of methods were very often better than the best of the individual methods in that subset (Supplementary Fig. 5c). These results indicate that individual team methods do provide complementary sets of predictions.

Top-performing methods exploit nonlinear modeling

The top-performing team from Aalto University and the University of Helsinki (co-authors on this manuscript) developed a machine-learning method that integrates multiple profiling data sets and knowledge-enhanced data representations into a nonlinear, probabilistic regression model to learn and predict drug sensitivities for all drugs simultaneously (Fig. 3 and Supplementary Note 1; source code provided as Supplementary Software). Their Bayesian multitask multiple kernel learning (MKL) method leveraged four machine-learning principles: kernelized regression, multiview learning, multitask learning, and Bayesian inference.

Figure 3: The method implemented by the best performing team.
Figure 3

(a) In addition to the six profiling data sets, three different categories of data views were compiled using prior biological knowledge, yielding in total 22 genomic views of each cell line. (b) Bayesian multitask MKL combines nonlinear regression, multiview learning, multitask learning and Bayesian inference. Nonlinear regression: response values were computed not directly from the input features but from kernels, which define similarity measures between cell lines. Each of the K data views was converted into an N×N kernel matrix Kk (k = 1,...,K), where N is the number of training cell lines. Specifically, the Gaussian kernel was used for real-valued data, and the Jaccard similarity coefficient for binary-valued data. Multiview learning: a combined kernel matrix K* was constructed as a weighted sum of the view-specific kernel matrices Kk, k = 1,...,K. The kernel weights were obtained by multiple kernel learning. Multitask learning: training was performed for all drugs simultaneously, sharing the kernel weights across drugs but allowing for drug-specific regression parameters, which for each drug consisted of a weight vector for the training cell lines and an intercept term. Bayesian inference: the model parameters were assumed to be random variables that follow specific probability distributions. Instead of learning point estimates for model parameters, the parameters of these distributions were learned using a variational approximation scheme.

The underlying model was kernelized regression, a regression approach that computes outputs from similarities between cell lines, which is analogous to the usage of kernel methods in classification tasks (e.g., support vector machines). In contrast, other regression approaches compute outputs directly from the input features. The kernel formulation28,29 has two advantages. First, it reduces the number of model parameters to match the number of samples (training cell lines) and not the number of features. Second, it captures nonlinear relationships between genomic and epigenomic features, and cell-line drug sensitivities.

In multiview learning, heterogeneous input data (views) are integrated into a single model. This makes it possible to include not only different profiling data sets but also various representations of the same data set. For example, gene expression values can be summarized at the pathway level. We use the term 'view' to describe these representations (analogous to views in a database). Besides the original profiling data sets, three types of computed data views were considered, including gene set summaries, data combinations, and data discretization (Fig. 3a). Sets of related genes, defined in the MSigDB27,30 collections C2 (curated gene sets) and CP (canonical pathways), were used to calculate aggregated gene set views (average value for expression data, otherwise maximum). Data combination views were calculated as the product of individual data sets or according to the PARADIGM algorithm31. Finally, discretized views were compiled by binarizing continuous measures. A total of 22 views were generated. For the kernelized regression, each of the views was converted into a kernel matrix containing pair-wise similarities between all cell lines. Gaussian kernels were used for real-valued views and Jaccard similarity coefficients for binary-valued views. To integrate the views, the team modeled a global similarity matrix as a weighted sum of the view-specific kernel matrices. This approach is known as multiple kernel learning or MKL32 (Fig. 3b, left). The kernel weights reflect the relevance of each view for predicting drug sensitivities; the corresponding model parameters are shared across drugs.

The sharing of information between drugs, implying simultaneous modeling of drug sensitivities across all the drugs, is called multitask learning33 (Fig. 3b, right). Here, the kernel weight parameters were shared, providing robustness to the overall model. The second set of model parameters comprises the core parameters of kernelized regression, which were drug-specific: for each drug, there was a vector of weights for the training cell lines and an individual intercept term. To handle the uncertainty resulting from the small sample size, all model parameters were learned by Bayesian inference, assuming for each model parameter a specific probability distribution, where parameters were learned using a computationally efficient variational approximation scheme (Supplementary Note 1).

After being benchmarked against the Genomics of Drug Sensitivity in Cancer (GDSC) data set3, the Bayesian multitask MKL method was applied to the NCI-DREAM test cell lines. By training the model with all 22 views, predictive performance was improved by 9% over using only the six profiling data sets, yielding a final wpc-index = 0.583 (one-sided, t-test from random predictions, FDR = 2.5 × 10−5; scaled wpc-index = 0.629).

The second-best performing team of Qian Wan and Ranadip Pal from Texas Tech University leveraged the strengths of random forest regression34 to account for nonlinearities in the NCI-DREAM data (Supplementary Note 1). First, an ensemble of unpruned regression trees with random feature selection was compiled based on a bootstrapped sampling of a given profiling data set. For each profiling data set, a final model based on averaging of predictions over the collection of trees was generated. Each model was then weighted according to its least-squares fit to the training drug sensitivity data. The final predictions were calculated as the weighted sum of all six profiling data set models, yielding a final wpc-index = 0.577 (one-sided, t-test, FDR = 7.2 × 10−5; scaled wpc-index = 0.620). For this approach, the most informative profiling data sets were gene expression followed by methylation.

Profiling data sets provide nonredundant predictive signals

We used the insights provided by participating teams in a postchallenge comparative analysis between the Bayesian multitask MKL method (kernel 1) and an elastic net to characterize the predictive power of the original six profiling data sets. Teams most often reported that gene expression microarrays carried the greatest weight in their models (Supplementary Note 1). We tested this observation by performing 50 independent simulations of the NCI-DREAM challenge, randomly splitting all data sets into 35 training and 18 test cell lines, balanced for breast cancer subtype. To establish a baseline performance, we chose an elastic net model because it had been used previously1, was widely used by teams (Supplementary Note 1), and could be easily applied off-the-shelf (glmnet R package35). Averaged across all tested drugs, we found that the RPPA data showed the highest performance for the elastic net, followed closely by gene expression data (Fig. 4a). The Bayesian multitask MKL performed better than the elastic net using the RPPA data (one-sided, Wilcoxon signed-rank test, FDR = 1.3 × 10−6), and Bayesian multitask MKL using gene expression data significantly outperformed the use of RPPA data (two-sided, Wilcoxon signed-rank test, FDR = 1.3 × 10−6). For both methods, the performance varied across individual drugs (Supplementary Fig. 6). We also examined the effect of profiling data sets on drug classes (as defined in Supplementary Table 8) and found that for Bayesian multitask MKL, the 'Signaling growth' drugs had higher predictive scores in general, with gene expression and RPPA data being the data sets with the most predictive power (Supplementary Fig. 6).

Figure 4: Performance comparison of data set views.
Figure 4

The top-performing method, Bayesian multitask MKL, and an elastic net predictor were trained on (a) the original profiling data sets, (b) computed views, (c) groups of data views, and (d) the fully integrated set of all data views. Boxplots represent the distribution of 50 random simulations matching the NCI-DREAM challenge parameters, where whiskers indicate the upper and lower range limit, and the black line, the median. (b) The computed views were derived from gene sets, combined data sets, calculated as the product of values between data sets, and discretizing continuous measures into binary values. (c) Data view groups were defined as all views derived from one profiling data set. (d) For Bayesian multitask MKL, the integration of all data views achieves the best performance. Gene expression is the most predictive profiling data set, slightly outperformed by gene set views of expression data and the integration of original and gene set expression data.

Between the six profiling data sets, we explored the issue of data complementarity and redundancy, specifically, which data set combinations provide performance gains over single data sets. For the Bayesian multitask MKL method, we found that exome sequencing data best complemented gene expression data, whereas for the elastic net, methylation data best complemented gene expression data. For both methods, all other data sets were best complemented by gene expression, to varying degrees (Supplementary Fig. 7). Additionally, by evaluating methods trained with five instead of the full six profiling data sets, we identified methylation as the most independent, nonredundant profiling data set because removing methylation showed the largest average drop in performance (Supplementary Figs. 7 and 8).

In addition to the original data sets, we explored the performance of computed data views, as defined in the previous section. For both methods, gene set views (CP and C2) showed improved performance for copy number variation (CNV) data compared to the original data. In contrast, discretization of RNA-seq data improved the performance only with Bayesian multitask MKL and not with the elastic net. Comparing all computed views, the gene set view (CP) of gene expression data achieved the best performance for both methods (Fig. 4b). Finally, we tested whether all views for a single profiling data set (original data set plus computed views) could be integrated to improve performance. For the elastic net, we only found a slight gain in performance for the RNA-seq and CNV groups, whereas the Bayesian multitask MKL method showed performance gains for all groups except for exome sequencing (Fig. 4c), with the top-performing group coming from gene expression data. Notably, the fully integrated model of all 22 data views improved performance against the gene expression group (one-sided, Wilcoxon signed-rank test, FDR = 7.3 × 10−7; Fig. 4d). Taken together, these results suggest that gene expression data provides the most predictive power for any individual profiling data set. Also, predictive power can be gained within a data set by generating new computational views that integrate across profiling data sets and incorporate prior knowledge. Notably, this improvement comes with no additional experimental cost (Supplementary Figs. 9 and 10).

A predictive signal can be identified for most drugs

Teams were scored according to their ability to rank cell lines across all 28 tested therapeutic compounds. Here, we explored teams' abilities to predict individual drug response. Inhibition of cell growth was predicted well for some compounds (e.g., bromopyruvate (glycolysis), PD184352 (MEK)), whereas for other compounds, teams generally performed poorly (e.g., chloroquinine (autophagy), FR180304 (ERK)) (Fig. 5a). To characterize factors that influence compound predictability, we measured the Pearson correlation between the pc-index and a compound's dynamic range (minimum to maximum −log10(GI50) values). A mild positive trend exists (ρ= 0.14), though it is not statistically significant (p = 0.49) (Fig. 5b). We found that proteasome inhibitors tend to be predicted more accurately than other drug classes (as defined in Supplementary Table 8), though with a relatively small number of compounds in each class, this analysis is not well-powered. One factor that did confound our assessment of individual drug performance was the number of −log10(GI50) values measured for a drug (Fig. 5b). That is, missing values and multiple cell lines with the same measured response resulted in underpowered, drug-specific statistics. This observation is the basis for weighting drugs to calculate the wpc-index score.

Figure 5: Prediction performance on individual drugs.
Figure 5

Prediction algorithms are indexed and colored according to Table 1. (a) The heatplot illustrates participant performance on individual drugs, grouped by drug class (values can be found in Supplementary Table 9). Drug weights, which take into account the number of missing values and the noise in the −log10(GI50) measurements, are displayed at the top of the heatplot. Team submissions are ordered according to their overall performance from best performer at the top of the list. (b) The dynamic range of drugs across all cell lines was compared to the median team score. The node size reflects the number of distinct −log10(GI50) values for each drug across all 53 cell lines. The node colors reflect mode-of-action classes. The gray horizontal line is the mean score of random predictions and the vertical gray line separates low dynamic range (<2) from high dynamic range (>2), where dynamic range for a drug is the maximum −log10(GI50) − minimum −log10(GI50). (c) The distribution of team scores (n = 44) for individual drugs was compared to the null model of random predictions (gray line where pc-index = 0.5). The red points correspond to the maximum possible pc index (pc index of gold standard in the test data). On average, 21/28 drugs performed better than the null model; using the Kolmogorov-Smirnov test, 16/28 drugs were significantly better than the null model (*FDR < 0.05; **FDR < 0.01; ***FDR < 0.001).

We further assessed the predictability of individual drugs by comparing the distribution of team predictions to a random model and found that 21/28 drugs performed better than the average null model, and 16/28 drugs were significantly better (Kolmogorov-Smirnov test, FDR < 0.05; Fig. 5c). This strongly indicates that a predictive signal is being identified by a majority of teams for more than half of the tested compounds. Further, these observations demonstrate that it is possible to identify predictive features for compounds representing diverse modes of action. We also quantified the gap in performance between team predictions and the best possible ranking (as defined by the rank order of the test cell lines). Across 28 compounds, the Bayesian multitask MKL method accounted for 73% of the maximum possible score, with the second-best performing team accounting for 71% of the maximum possible signal. Although promising, this indicates that these drug sensitivity predictions could benefit from further refinement.

Discussion

Over a period of 5 months, 127 researchers focused their time and efforts on addressing the challenge of drug sensitivity prediction. To our knowledge, no previous studies have assessed a comprehensive benchmarked set of algorithms for predicting therapeutic response based on genomic, epigenomic, and proteomic profiles of untreated cells. The Bayesian multitask MKL method provides an excellent example of how the NCI-DREAM challenge drove innovation in algorithm development. Considering all 44 submitted methods, the insights gained provide a valuable resource for future algorithm development (Supplementary Note 1).

In particular, our analysis of this collection of algorithms revealed several insights about predicting drug sensitivity. First, we found that modeling nonlinearities in the data was a common component of top-performing methods. Second, the Bayesian multitask MKL method showed improved performance by learning weights for the input data sets. Sharing the weights across drugs provided greater robustness of the prediction model and resulted in an increased overall performance, particularly for the drugs with many missing values. Finally, the application of prior knowledge, particularly in the form of biological pathways, improved drug sensitivity predictions. This was demonstrated in the Bayesian multitask MKL method through data views, though many top-performing teams implemented similar approaches to leverage pathway information.

We observed that gene expression was the most informative data set in many approaches, which may partly reflect the fact that analysis tools for this data type are more abundant and advanced. That is, we do not yet know the best approaches to extract predictive information from the other large profiling data sets; in particular the sparsity of exome sequencing data requires novel analysis methods36. However, when combined with expression data, these other data sets can enhance prediction performance.

The analysis of individual compounds showed that predictors of response could be robustly identified for the majority of compounds tested. This suggests a prioritization scheme for identifying compounds and their associated signatures with the most promise for validation in patient populations. Both targeted and nontargeted compounds, as well as those with both high and low dynamic ranges of response could be predicted, indicating that predictive features are present in the profiling data sets for a diverse array of drug mechanisms.

The −log10(GI50) drug response measurement used in this study represents one available metric to quantify drug response. Recent studies have demonstrated that dose-response curves can be parameterized in many meaningful ways1,37. It is possible that applying the algorithms assessed here to other parameters of the curves would yield more robust predictions for some of the compounds for which predictions were poor. In addition, the −log10(GI50) reflects the combined effect of growth inhibition and apoptosis, two related but distinct processes that can be modeled separately, and even targeted separately as a cancer treatment strategy38. Expanding the measurements to include endpoints that mediate oncogenic behavior of cells39 would allow for improved model construction and has recently been shown to be experimentally and technologically feasible40.

A limitation of this work is the small number of cell lines and compounds tested. The efforts by NCI-DREAM participants have laid the groundwork for the development of improved drug sensitivity models that can be applied to newly generated data sets1,3. Another consideration is that preclinical work is only a very early step in the translation to clinical samples. Now that genomic, epigenomic and/or proteomic profiles are frequently a component of clinical trials (e.g., I-SPY 2 Trial: http://www.ispy2.org/), these data will be available to test and refine models developed from this challenge in human trials. Moreover, participants were not given any information about the mode of action, target or chemical structure of the compounds, which could be included as additional features for the models23.

The success of precision medicine will depend on our ability to translate large compendia of genomic, epigenomic, and proteomic data into clinically actionable predictions. Examples such as the recent Sage Bionetworks-DREAM breast cancer prognosis challenge41 and this NCI-DREAM drug sensitivity challenge demonstrate the evolution of challenge-based competitions, resulting in rapid advancement of robust algorithms and establishment of benchmarked models. Equally important, challenge-based competitions build the critical mass of collaborative scientists necessary to address fundamental biomedical questions42. The evolution of the DREAM project will continue as the challenges in biomedical research expand to the genome scale.

Methods

Challenge data and gold standard.

The NCI-DREAM drug sensitivity prediction challenge is outlined in Figure 1. A total of seven data sets were provided for 53 breast cancer cell lines, as discussed in detail in two recent publications: Heiser et al.4 and Daemen et al.23. The cell lines were selected to represent the major, clinically relevant subtypes of breast cancer, including luminal, basal, claudin-low, ERBB2-amplified, and nonmalignant. The drugs were selected based on data availability (on average, drugs were tested on 80% of the 53 cell lines) and novelty (drug response data were unpublished, not distributed throughout the community of participants, and not available from other sources (Supplementary Note 4)). Most of the included drugs have not been tested clinically in breast cancer, and therefore have the potential to serve as novel therapeutics.

A total of six genomic, epigenomic and proteomic profiling data sets were collected from untreated cells in growth conditions. Descriptions of each profiling data set can be found in the annotation files associated with each data set supplied through the DREAM website (http://www.the-dream-project.org/). Not all profiling data were collected for every cell line, and drugs were not equally sampled across all of the cell lines.

  1. DNA copy-number variation (CNV). Affymetrix Genome-Wide Human SNP6.0 Array. Copy number ratios were estimated relative to a set of 20 normal samples, and data were segmented using circular binary segmentation (CBS)43;

  2. Transcript expression values. Affymetrix GeneChip Human Gene 1.0 ST microarrays were processed using the R package aroma.affymetrix44 (over 18,000 expression values);

  3. Whole exome sequencing (exome seq). Mutation status was obtained from exome-capture sequencing (Agilent Sure Select system). Mutations across all cell lines were filtered as follows: (i) average sum of the base quality scores of all mismatches in the reads containing the mutant allele ≤ 20; (ii) average number of other mismatches in the reads ≤ 1.5; (iii) average distance of the mutant alleles to the 3′ end of their respective reads between 0.2 and 0.8; (iv) mutant allele read support ≥ 4; (v) number of reads per variant supporting either the reference or mutant allele < 400 (over 33,000 reported mutations);

  4. RNA sequencing data (RNA-seq). RNA-seq libraries were prepared using the TruSeq RNA Sample Preparation Kit (Illumina) and Agilent Automation NGS system per manufacturers' instructions. Expression analysis was performed with the ALEXA-seq software package45 (just under 37,000 RNAs);

  5. DNA methylation data. The Illumina Infinium Human Methylation27 BeadChip Kit was used for the genome-wide detection of 27,578 CpG loci, spanning 14,495 genes46. GenomeStudio Methylation Module v1.0 was used to express the methylation for each CpG locus as a value between 0 (completely unmethylated) and to 1 (completely methylated) (over 27,000 CpGs);

  6. RPPA. An antibody-based method to quantitatively measure protein abundance. RPPA data were generated and preprocessed as previously described47 (131 proteins assayed).

In addition to the profiling data, drug response for each of the 53 cell lines to 28 drugs was tested. Dose-response curves were generated and the GI50[M] was calculated. To estimate the GI50, a series of assays were done, as previously described48. Briefly, cells were treated for 72 h with a set of nine doses of each compound in 1:5 serial dilution. Cell viability was determined using the Cell Titer Glo assay. We used nonlinear least-squares to fit the data with a Gompertz curve. The fitted curve was transformed into a GI curve using the method (http://dtp.nci.nih.gov/branches/btb/ivclsp.html) described in Monks, et al.49. In cases where the underlying growth data were of high quality, but the GI50 was not reached, the values were set to the highest concentration tested. The drug response data were filtered according to previously described criteria4. All reported drug response values and calculations for scoring were done using −log10(GI50). The complete set of unfiltered raw drug response data is in Supplementary Table 2.

Participants were supplied with the full set of profiling data for all of the cell lines and drug response data for 35 (of the 53) cell lines for all 28 drugs. The gold-standard evaluation data set consisted of drug response data for the remaining 18 cell lines, which were hidden from the participants. Cell lines were assigned to the training and test data sets to ensure a balanced set of breast cancer subtypes.

Participants were challenged to predict a ranked list of the most sensitive (to be ranked first) to most resistant (to be ranked last) cell lines for each individual drug across all the 18 test cell lines. We note that the drug response values, −log10(GI50), ranked from highest to lowest values, correspond to a ranking of the most-sensitive to the most-resistant cell lines. Assessment of predictions was based on participant's ranking of the 18 test cell lines. Participants supplied their final submission as a comma-separated text file with the drugs listed as columns and cell lines listed as rows. The cells in the matrix represent ranks of each cell line for a given drug.

Team scoring.

Drug response measurements, −log10(GI50), are subject to noise. To account for these uncertainties, a pooled variance,

was calculated for each tested drug individually, d, over n = 53 cell lines, where ri and are the replicate number and variance of the ith cell line, respectively. There were several drugs (bromopyruvate (glycolysis), chloroquine (autophagy), GW5074 (RAF1), and QNZ (NFκB)) with low replicate numbers; in these instances, the global pooled variance across all drugs and cell lines was used. Values used to calculate the pooled variance can be found in Supplementary Table 10. The pooled variance was then taken into account when scoring team submissions as described in the following section.

The final team submissions were evaluated using two independent scoring methods. The first scoring method, a weighted, probabilistic concordance-index (wpc-index), was used to report the final team rankings of the challenge. The second method, a resampled Spearman correlation, was used to verify the consistency between team rankings based on a separate scoring method and implementation. Team scores were then subjected to a resampled, robustness analysis to ensure team rankings were not affected by perturbations to the gold-standard test cell lines. Team scores were based on the set of 18 test cell lines.

Weighted probabilistic concordance-index (wpc-index).

The concordance index (c-index) is a nonparametric scoring method that provides a measure of similarity between two lists of measurements or ranks24. For a detailed description of the scoring methodology, see Supplementary Note 3.

Resampled Spearman correlation.

The key idea motivating this scoring metric is to compare the predicted ranked list for each drug, d, and n cell lines (n = 18 for the set of test cell lines), Rd = (r1, r2,..., rn) against an ensemble of t different possible realizations of the gold standard, , for the same drug and cell lines, where each realization Gd is defined as Gd = (g1, g2,..., gn). Each of the possible t realizations of the gold-standard samples a drug's −log10(GI50) dose in a cell line from the normal distribution, N(xd,n, sd) where xd,n is the sample mean of the drug response for d and cell line n, and sd is the pooled s.d. for d over all tested cell lines. The ensemble of gold standards, , is then converted into ranked gold-standard cell lines, . Afterwards we compared these rank gold-standard cell lines to the predicted ranks, Rd:

where and are the mean gold standard ranks and predicted rank, respectively.

Robustness analysis.

To ensure team rankings are robust to perturbations in the gold-standard data set, a subsampling analysis was performed. A set of t = 10,000 evaluation data sets, , was generated where 10% of the gold-standard data set, G, was randomly masked to create G′. All predictions in E were scored to create an empirical null distribution of wpc-index scores. Individual teams were rescored using G′ and compared to the null distributions using a single-sample, two-sided, Student's t-test. FDRs were calculated using the Benjamini-Hochberg correction. In addition to the wpc-index, on each iteration, submissions were re-ranked to create a distribution of team ranks, which were compared using the Wilcoxon signed-rank test.

Data view analysis.

Besides the six profiling data sets supplied in the challenge, additional views were constructed by challenge organizers (discretized RNA-seq) and by the top-performing team (discretized exome sequencing, gene set summaries for individual data types and genewise combination of two or more data sets). The analysis of individual and grouped data views was done using the Bayesian multitask MKL method from the top-performing team and an elastic net linear regression implemented in the R package, glmnet35. A total of 50 simulations of the challenge were run by randomly selecting 35 training and 18 test cell lines, keeping the subtypes of cell lines balanced.

At each iteration of the challenge simulations, the Bayesian multitask MKL method was applied using a single view or a group of views as input data. The elastic net was learned using the same training and test cell lines as the Bayesian multitask MKL method and modeling each drug separately. For each selection of input views and each drug, an elastic net regression model was learned, where regularization parameters were selected by fivefold cross-validation on the training data, using α values from 0 to 1 in increments of 0.1 and the default λ sequence. The final prediction model was trained on all training cell lines, using the parameters with minimal cross-validation error. Elastic net models were first trained using all features in a data set, but performance was poor due to the high dimensionality compared to low sample size. Thus, for data sets with more than 5,000 features, only the top 10% most-variable features were used. For the analysis of multiple grouped views, a simple data concatenation approach was first tried, but resulted in decreased performance due to an increase in the number of input features. Therefore, a fraction of top-varying features was kept for each view when integrating K views. Statistical significance was calculated using the Wilcoxon signed-rank test and FDR corrected.

Data deposition.

The NCI-DREAM data set is a subset of the data reported in Daemen et al.23 Genome copy number data has been deposited at the European Genome-Phenome Archive (http://www.ebi.ac.uk/ega/), hosted at the EBI (accession numbers EGAS00000000059 and EGAS00001000585). Gene expression data for the cell lines were derived from Affymetrix GeneChip Human Genome U133A and Affymetrix GeneChip Human Exon 1.0 ST arrays. Raw data are available in ArrayExpress (http://www.ebi.ac.uk/arrayexpress), hosted at the EBI (accession number E-TABM-157 and E-MTAB-181). RNA-seq and exome-sequencing data can be accessed at the Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/), accession number GSE48216. Genome-wide methylation data for the cell lines are also available through GEO, accession number GSE42944. Scripts to perform the wpc-index and resampled Spearman scoring can be found on the DREAM website (http://www.the-dream-project.org/). Source code for the Bayesian multitask MKL method can be found as Supplementary Software.

Accession codes.

EBI: EGAS00000000059 and EGAS00001000585, E-TABM-157 and E-MTAB-181. GEO: GSE48216 and GSE42944.

Change history

  • 10 October 2014

    In the version of this article initially published online, in Table 1, the FDRs should all have had negative rather than positive exponents. Several citations were incorrect, including on p.1, two lines from end of page, “proposed1,3,20,21,22” should have been “proposed1,3,20–23”; p.2, first paragraph of Results, “abundance23” should have been “abundance20”; p.9, end of penultimate paragraph, “models22” should have been “models23.” The errors have been corrected for the print, PDF and HTML versions of this article.

Accessions

Primary accessions

Gene Expression Omnibus

References

  1. 1.

    et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

  2. 2.

    Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).

  3. 3.

    et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).

  4. 4.

    et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA 109, 2724–2729 (2012).

  5. 5.

    International Cancer Genome Consortium. et al. International network of cancer genome projects. Nature 464, 993–998 (2010).

  6. 6.

    et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).

  7. 7.

    et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961 (2013).

  8. 8.

    The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813–823 (2006).

  9. 9.

    et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505–509 (2012).

  10. 10.

    et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).

  11. 11.

    & Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378, 1812–1823 (2011).

  12. 12.

    et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869–10874 (2001).

  13. 13.

    et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).

  14. 14.

    et al. Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene 31, 333–341 (2012).

  15. 15.

    et al. SEER Cancer Statistics Review, 1975–2010 (National Cancer Insitute, Bethesda, MD, 2013).

  16. 16.

    et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012).

  17. 17.

    et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).

  18. 18.

    et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4, e6146 (2009).

  19. 19.

    et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515–527 (2006).

  20. 20.

    et al. Modeling precision treatment in breast cancer. Genome Biol. 14, R110 (2013).

  21. 21.

    et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5, 853–867 (2006).

  22. 22.

    & Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res. 73, 1699–1708 (2013).

  23. 23.

    et al. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS ONE 8, e61318 (2013).

  24. 24.

    Regression Modeling Strategies (Springer, New York, 2001).

  25. 25.

    et al. Wisdom of crowds for robust gene network inference. Nat. Methods 9, 796–804 (2012).

  26. 26.

    & KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).

  27. 27.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).

  28. 28.

    & Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond (MIT Press, 2001).

  29. 29.

    & Kernel Methods for Pattern Analysis (Cambridge University Press, New York, NY, 2004).

  30. 30.

    et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).

  31. 31.

    et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237–i245 (2010).

  32. 32.

    & Multiple kernel learning algorithms. J. Mach. Learn. Res. 12, 2211–2268 (2011).

  33. 33.

    Multitask learning. Mach. Learn. 28, 41–75 (1997).

  34. 34.

    Random forests. Mach. Learn. 45, 5–32 (2001).

  35. 35.

    , & Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).

  36. 36.

    , , & Simultaneous identification of multiple driver pathways in cancer. PLoS Comput. Biol. 9, e1003054 (2013).

  37. 37.

    , , , & Comparing drug activity across cell line banks reveals systematic variation in properties other than potency. Nat. Chem. Biol. 9, 708–714 (2013).

  38. 38.

    et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med. 18, 1503–1510 (2012).

  39. 39.

    & Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

  40. 40.

    , , & Expanding the diversity of image-based RNAi screen applications using cell spot microarrays. Microarrays 2, 97–114 (2013).

  41. 41.

    et al. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci. Transl. Med. 5, 181re1 (2013).

  42. 42.

    & Seeking the wisdom of crowds through challenge-based competitions in biomedical research. Clin. Pharmacol. Ther. 93, 396–398 (2013).

  43. 43.

    & A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657–663 (2007).

  44. 44.

    , & A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 25, 2149–2156 (2009).

  45. 45.

    et al. Alternative expression analysis by RNA sequencing. Nat. Methods 7, 843–847 (2010).

  46. 46.

    et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 71, 6195–6207 (2011).

  47. 47.

    et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512–2521 (2006).

  48. 48.

    et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med. 7, 77 (2009).

  49. 49.

    et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83, 757–766 (1991).

Download references

Acknowledgements

The data were kindly provided before publication for this challenge by J.W.G. We acknowledge the contributions of all participants in the co-organized NCI and DREAM Summit held on April 23, 2012, for the development of the challenge (http://www.the-dream-project.org/sites/the-dream-project.org/files/documents/dream7/dream_participant_list.docx). This work is supported in part by the following: MaGNeT grant (5U54CA121852-08); National Institutes of Health, National Cancer Institute grant U54 CA 112970; Stand Up To Cancer-American Association for Cancer Research Dream Team Translational Cancer Research grant SU2C-AACR-DT0409; Prospect Creek Foundation; Howard Hughes Medical Institute (HHMI); and The Academy of Finland (Finnish Center of Excellence in Computational Inference Research COIN, grant nos. 251170 and 140057).

We acknowledge the computational resources provided by Aalto Science-IT project.

Author information

Author notes

    • James C Costello
    •  & James C Costello

    Present address: Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

    • James C Costello
    • , Laura M Heiser
    •  & Elisabeth Georgii

    These authors contributed equally to this work.

Affiliations

  1. Howard Hughes Medical Institute, Boston University, Boston, Massachusetts, USA.

    • James C Costello
    • , James C Collins
    •  & James J Collins
  2. Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA.

    • James C Costello
    • , James C Collins
    •  & James J Collins
  3. Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA.

    • Laura M Heiser
    • , Nicholas J Wang
    •  & Joe W Gray
  4. Helsinki Institute for Information Technology HIIT, Department of Information and Computer Science, Aalto University, Espoo, Finland.

    • Elisabeth Georgii
    • , Mehmet Gönen
    • , Muhammad Ammad-ud-din
    • , Suleiman A Khan
    •  & Samuel Kaski
  5. European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, UK.

    • Michael P Menden
    • , Thomas Cokelaer
    •  & Julio Saez-Rodriguez
  6. Department of Systems Biology, Center for Computational Biology and Bioinformatics, Columbia University, New York, New York, USA.

    • Mukesh Bansal
    •  & Andrea Califano
  7. Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.

    • Petteri Hintsanen
    • , John-Patrick Mpindi
    • , Olli Kallioniemi
    • , Tero Aittokallio
    •  & Krister Wennerberg
  8. Helsinki Institute for Information Technology HIIT, Department of Computer Science, University of Helsinki, Helsinki, Finland.

    • Antti Honkela
    •  & Samuel Kaski
  9. Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.

    • James C Collins
    •  & James J Collins
  10. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

    • Dan Gallahan
    •  & Dinah Singer
  11. IBM T.J. Watson Research Center, IBM, Yorktown Heights, New York, USA.

    • Gustavo Stolovitzky
  12. Swiss Institute for Experimental Cancer Research (ISREC), Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.

    • Jean-Paul Abbuehl
    • , Jonathan Bernard
    • , Krisztian Homicsko
    •  & Anguraj Sadanandam
  13. Quantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

    • Jeffrey Allen
    • , Beibei Chen
    • , Min Kim
    • , Hao Tang
    • , Guanghua Xiao
    • , Yang Xie
    •  & Jichen Yang
  14. Departments of Genetics and Bioengineering, Stanford University, Stanford, California, USA.

    • Russ B Altman
    •  & Assaf Gottlieb
  15. Department of Computer Science and Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

    • Shawn Balcome
    • , Raamesh Deshpande
    • , Chad L Myers
    • , Wen Wang
    •  & Tian Xia
  16. Department of Computer Science, Stanford University, Palo Alto, California, USA.

    • Alexis Battle
    • , David A Knowles
    •  & Daphne Koller
  17. Unilever Centre, Cambridge University, Cambridge, UK.

    • Andreas Bender
  18. Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, Massachusetts, USA.

    • Bonnie Berger
  19. Department of Statistics, University of Pune, Pune, India.

    • Madhuchhanda Bhattacharjee
  20. School of Mathematics and Statistics, University of Hyderabad, Hyderabad, India.

    • Madhuchhanda Bhattacharjee
  21. Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC, USA.

    • Krithika Bhuvaneshwar
    • , Robinder Gauba
    • , Yuriy Gusev
    • , Michael Harris
    • , Subha Madhavan
    • , Lei Song
    •  & Difei Wang
  22. Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, W. Lafayette, Indiana, USA.

    • Andrew A Bieberich
    •  & V Jo Davisson
  23. Department of Statistics, University of Wisconsin, Madison, Wisconsin, USA.

    • Fred Boehm
    • , Haoyang Fan
    • , Nicholas Henderson
    • , Sunduz Keles
    • , Christina Kendziorski
    • , Michael A Newton
    • , Tram Ta
    • , Zhishi Wang
    •  & Chandler Zuo
  24. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin, USA.

    • Fred Boehm
    • , Haoyang Fan
    • , Nicholas Henderson
    • , Sunduz Keles
    • , Christina Kendziorski
    • , Michael A Newton
    • , Tram Ta
    • , Zhishi Wang
    •  & Chandler Zuo
  25. Department of Computer Science and Engineering, Michigan State University, East Lansing, Michigan, USA.

    • Christina Chan
  26. Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, Michigan, USA.

    • Christina Chan
  27. Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan, USA.

    • Christina Chan
  28. Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA.

    • Ting-Huei Chen
    • , Min Jin Ha
    •  & Wei Sun
  29. Korea Advanced Institute of Science and Technology, Daejeon, Korea.

    • Jaejoon Choi
    • , Woochang Hwang
    • , Junho Kim
    •  & Junehawk Lee
  30. Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

    • Luis Pedro Coelho
  31. Department of Medicine, Dan L. Duncan Center Division of Biostatistics, Baylor College of Medicine, Houston, Texas, USA.

    • Chad J Creighton
  32. Translational Medicine, Millennium Pharmaceuticals, Cambridge, Massachusetts, USA.

    • Jike Cui
    • , Bin Li
    • , Hyunjin Shin
    •  & William Trepicchio
  33. Center for Integrated Bioinformatics, Drexel University, Philadelphia, Pennsylvania, USA.

    • Will Dampier
    • , Richard Pestell
    •  & Aydin Tozeren
  34. Department of Mathematical Modelling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium.

    • Bernard De Baets
    • , Michiel Stock
    •  & Willem Waegeman
  35. Department of Information Engineering, University of Padova, Padova, Italy.

    • Barbara DiCamillo
    • , Francesco Sambo
    •  & Gianna Maria Toffolo
  36. Computer and Information Science Department, IUPUI, Indianapolis, Indiana, USA.

    • Murat Dundar
  37. National Center for Mathematics and Interdisciplinary Sciences, Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, China.

    • Zhana Duren
    • , Yong Wang
    • , Shihua Zhang
    • , Xiang-Sun Zhang
    •  & Junfei Zhao
  38. Jefferson Kimmel Cancer Center, Drexel University, Philadelphia, Pennsylvania, USA.

    • Adam Ertel
  39. Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.

    • Hongbin Fang
    •  & Ming Tan
  40. Department of Physics, University of Marburg, Marburg, Germany.

    • Michael Grau
  41. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Leng Han
    • , Jun Li
    • , Han Liang
    • , Yanxun Xu
    •  & Yuan Yuan
  42. Department of Computer Science and Engineering, Michigan State University, East Lansing, Michigan, USA.

    • Hussein A Hejase
  43. Department of Bioengineering and Institute for Genomic Biology, University of Illinois, Champaign-Urbana, Illinois, USA.

    • Jack P Hou
    •  & Jian Ma
  44. Leiden Academic Center for Drug Research, University of Leiden, Leiden, Netherlands.

    • Adriaan P IJzerman
    •  & Eelke B Lenselink
  45. Izmir Institute of Technology, Izmir, Turkey.

    • Bilge Karacali
  46. Division of Biostatistics, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

    • Youngchul Kim
    •  & Jae K Lee
  47. Korea Institute of Science and Technology Information, Daejeon, Korea.

    • Junehawk Lee
  48. Buck Institute, Novato, California, USA.

    • Biao Li
    •  & Sean Mooney
  49. CAS-MPG Partner Institute for Computational Biology, Key Laboratory of Computational Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, P.R. China.

    • Jun Li
  50. Graduate Program in Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, Texas, USA.

    • Han Liang
    •  & Yuan Yuan
  51. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

    • Subha Madhavan
    •  & Difei Wang
  52. ChEMBL Group, The EMBL-European Bioinformatics Institute, Cambridge, UK.

    • John P Overington
    •  & Gerard J P van Westen
  53. Electrical and Computer Engineering, Texas Tech University, Lubbock, Texas, USA.

    • Ranadip Pal
    •  & Qian Wan
  54. Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, Massachusetts, USA.

    • Jian Peng
  55. IBM Almaden Research Center, IBM Almaden Research Center, San Jose, California, USA.

    • Robert J Prill
  56. Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Peng Qiu
  57. Bindley Bioscience Center, Purdue University, W. Lafayette, Indiana, USA.

    • Bartek Rajwa
  58. Department of Animal and Avian Science, University of Maryland, College Park, Maryland, USA.

    • Jiuzhou Song
  59. Embedded Systems Laboratory (ESL), Institute of Electrical Engineering, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.

    • Arvind Sridhar
  60. Department of Mathematics and Statistics, Georgetown University, Washington, DC, USA.

    • Mahlet Tadesse
  61. The University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado, USA.

    • Dan Theodorescu
  62. Centre for Computational Biology, Mines ParisTech, Fontainebleau, France.

    • Nelle Varoquaux
    • , Jean-Philippe Vert
    •  & Thomas Walter
  63. Institut Curie, Paris, France.

    • Nelle Varoquaux
    • , Jean-Philippe Vert
    •  & Thomas Walter
  64. INSERM U900, Paris, France.

    • Nelle Varoquaux
    • , Jean-Philippe Vert
    •  & Thomas Walter
  65. Janssen Pharmaceutica, Beerse, Belgium.

    • Joerg K Wegner
    •  & Herman W T van Vlijmen
  66. Department of Biostatistics and Computational Biology, Rochester University Medical Center, Rochester, New York, USA.

    • Tongtong Wu
  67. Department of Statistics, Rice University, Houston, Texas, USA.

    • Yanxun Xu

Consortia

  1. NCI DREAM Community

    List of participants and affiliations appear at the end of the paper.

Authors

  1. Search for James C Costello in:

  2. Search for Laura M Heiser in:

  3. Search for Elisabeth Georgii in:

  4. Search for Mehmet Gönen in:

  5. Search for Michael P Menden in:

  6. Search for Nicholas J Wang in:

  7. Search for Mukesh Bansal in:

  8. Search for Muhammad Ammad-ud-din in:

  9. Search for Petteri Hintsanen in:

  10. Search for Suleiman A Khan in:

  11. Search for John-Patrick Mpindi in:

  12. Search for Olli Kallioniemi in:

  13. Search for Antti Honkela in:

  14. Search for Tero Aittokallio in:

  15. Search for Krister Wennerberg in:

  16. Search for James J Collins in:

  17. Search for Dan Gallahan in:

  18. Search for Dinah Singer in:

  19. Search for Julio Saez-Rodriguez in:

  20. Search for Samuel Kaski in:

  21. Search for Joe W Gray in:

  22. Search for Gustavo Stolovitzky in:

Contributions

J.C.C., M.P.M., L.M.H., M.B., D.G., D.S., J.S.-R., J.J.C., J.W.G. and G.S. designed the challenge. The top-performing approach was designed by E.G., M.G., M.A., P.H., S.A.K., J.-P.M., O.K., A.H., T.A., K.W. and S.K. Data analysis for the top-performing approach was conducted by E.G., M.G., M.A., P.H., S.A.K. and S.K. M.G. and S.K. designed the Bayesian model and M.G. implemented the inference algorithm for the top-performing approach. The NCI-DREAM Community provided drug sensitivity predictions and Supplementary Note 1. descriptions. J.C.C., L.M.H. and M.P.M. performed analysis of challenge predictions. J.C.C., L.M.H., E.G., M.P.M., J.S.-R., S.K. and G.S. interpreted the results of the challenge and performed follow-up analyses for the manuscript. L.M.H., N.J.W. and J.W.G. generated experimental data. J.C.C., L.M.H., E.G., M.G., M.P.M., J.J.C., J.S.-R., S.K., J.W.G. and G.S. wrote the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Samuel Kaski or Joe W Gray or Gustavo Stolovitzky.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–11 and Supplementary Notes 1–4

Excel files

  1. 1.

    Supplementary Tables

    Supplementary Tables 1–10

Zip files

  1. 1.

    Supplementary Software

    Supplementary Software - Top performing team code.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.2877

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing